Study of FORE8394 for cancers with BRAF changes
Part of Cancer, Digestive system, Hormones & metabolism, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new drug, FORE8394, for people whose cancers have a change in the BRAF gene. It may be an option if you have a solid tumor or brain tumor that has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 8 years or older and weigh at least 55 pounds (25 kg).
- Your tumor has a specific change in the BRAF gene (like a fusion or mutation).
- You have tried standard treatments, or they aren't right for you.
- You must be willing to provide a small piece of your tumor for testing.
- You need to be able to swallow pills (the drug is taken by mouth).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 trial studies how PF-07799544 works and what dose is safest in people with advanced cancer that has a specific genetic change called BRAF V600. You may receive it alone or with another treatment, depending on the tumor group, to see if it can treat the cancer.
This trial tests a new drug, HSK42360, for people with advanced solid tumors that have a specific gene change called BRAF V600. It may be an option if other treatments have stopped working.
This trial tests dabrafenib plus trametinib in people whose solid tumors have a BRAF V600E mutation that cannot be fully removed by surgery or has spread. It looks at whether these targeted medicines can shrink tumors and control the disease.
This study tests a new targeted drug called plixorafenib, either alone or combined with another drug (retifanlimab), for people with a BRAF-mutated brain tumor. The goal is to see if the drug can reach the brain and control the tumor, while checking for side effects.
This Phase 1 trial studies PF-07799933, a new medicine, in people whose advanced solid tumors have specific BRAF genetic changes. It may help if your cancer has continued to grow after standard treatments, and there may be specific options depending on your cancer type and past therapies.
This trial tests a drug called Belvarafenib for people with brain tumors that have a BRAF gene change (mutation). The drug targets this specific change to try to shrink or control the tumor. It is for patients whose brain tumor has come back or hasn't responded to other treatments.
Hear when a new HGG trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.